Document is current
Any future updates will be listed below
-
Authors
,
Strydom, Andre http://orcid.org/0000-0002-2502-6704
Heslegrave, Amanda
Startin, Carla M.
Mok, Kin Y.
Hardy, John
Groet, Jurgen
Nizetic, Dean
Zetterberg, Henrik
-
Funding
Funding for this research was provided by:
Wellcome Trust (098330/Z/12/Z)
- License Information
-
More Information
Article History
Received: 16 February 2018
Accepted: 14 March 2018
First Online: 10 April 2018
Ethics approval and consent to participate
: The North West Wales National Health Service (NHS) Research Ethics Committee provided ethical approval for a longitudinal study of cognitive ability and dementia in DS (13/WA/0194). For those with decision-making capacity, written consent was obtained, whereas for those who did not have decision-making capacity, a consultee indicated their agreement to participation.
: AS has consulted for Ono Pharmaceutical Co., is an adviser to the UK Down Syndrome Association, and is an advisory board member of the LuMind Research Down Syndrome Foundation (USA). HZ has served on advisory boards of Roche Diagnostics, Eli Lilly, and Teva and is a cofounder of Brain Biomarker Solutions with Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
